List of Excipients in Branded Drug JADENU

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	JADENU	deferasirox	0078-0654	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	JADENU	deferasirox	0078-0654	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	JADENU	deferasirox	0078-0654	MAGNESIUM STEARATE
Novartis Pharmaceuticals Corporation	JADENU	deferasirox	0078-0654	POLOXAMER 188
Novartis Pharmaceuticals Corporation	JADENU	deferasirox	0078-0654	POVIDONE K30
Novartis Pharmaceuticals Corporation	JADENU	deferasirox	0078-0654	SILICON DIOXIDE

JADENU Excipient Strategy, Formulation Patents, Generic Competition, and Commercial Opportunities

Last updated: September 27, 2026

JADENU is a film-coated tablet and oral granule formulation of deferasirox, an iron chelator marketed by Novartis. Its commercial formulation strategy replaces EXJADE’s dispersible-tablet presentation with a swallowable dosage form that improves administration convenience and changes dose conversion, food instructions, and excipient requirements. The main commercial opportunities now sit in generic deferasirox, pediatric and adherence-oriented presentations, excipient supply, formulation improvement, and manufacturing services rather than biosimilar development.

What is JADENU and how does its formulation differ from EXJADE?

JADENU contains deferasirox, an orally active iron chelator used to treat chronic transfusional iron overload and iron overload associated with non-transfusion-dependent thalassemia. The FDA approved JADENU in 2015 as a film-coated tablet and later approved JADENU Sprinkle granules for oral administration.[1]

Product	Dosage form	Administration	Commercial formulation issue
EXJADE	Dispersible tablet	Dispersed in liquid before administration	Preparation burden, taste, administration time
JADENU	Film-coated tablet	Swallowed whole, with or without a light meal	Improved convenience and portability
JADENU Sprinkle	Oral granules	Sprinkled onto soft food	Pediatric and swallowing-related opportunity

JADENU has higher systemic exposure than EXJADE at equivalent milligram doses. The labeled conversion is generally 30 mg/kg/day of EXJADE to 14 mg/kg/day of JADENU, and 20 mg/kg/day of EXJADE to 14 mg/kg/day of JADENU Sprinkle, subject to clinical monitoring.[1]

The dosage conversion creates a formulation-driven commercial distinction. Generic manufacturers must match the relevant reference product, strength, dosage form, bioequivalence profile, and labeling pathway. A generic JADENU tablet is not interchangeable in development terms with a generic EXJADE dispersible tablet.

Which excipients are used in JADENU tablets?

The JADENU tablet core uses a conventional immediate-release platform with excipients selected for wetting, breakup, flow, compaction, lubrication, and manufacturing consistency.

Excipient class	JADENU excipient	Formulation function
Diluent and compression aid	Microcrystalline cellulose	Tablet mass, compactibility, mechanical strength
Superdisintegrant	Crospovidone	Rapid tablet breakup and liquid penetration
Binder	Povidone	Granule and tablet cohesion
Surfactant	Sodium lauryl sulfate	Wetting of the poorly water-soluble active ingredient
Glidant	Colloidal silicon dioxide	Powder flow and content-uniformity support
Lubricant	Magnesium stearate	Ejection from tablet tooling
Film former	Hypromellose	Protective and cosmetic coating
Opacifier or pigment	Titanium dioxide and, for certain strengths, iron oxide pigments	Appearance and product identification
Coating aid or plasticizer	Talc and macrogol	Coating processability and film performance

The exact inactive-ingredient presentation can vary by strength and jurisdiction. U.S. product labeling identifies the core excipient system and film-coating components; commercial due diligence should rely on the current FDA label, DailyMed record, and approved product-specific labeling.[1,2]

Why is sodium lauryl sulfate important in the JADENU excipient strategy?

Deferasirox has limited aqueous solubility, making wetting and dissolution central formulation risks. Sodium lauryl sulfate can improve powder wetting and reduce interfacial resistance between the drug particles and dissolution medium. In a high-dose oral product, this function can materially affect dissolution performance and bioequivalence.

The excipient creates several development constraints:

1. Its concentration must be controlled because excess surfactant can affect gastrointestinal tolerability and dissolution behavior.
2. Its distribution must remain uniform across the blend and tablet.
3. Supplier grade, particle size, moisture, and purity can influence dissolution and tablet robustness.
4. Changes in sodium lauryl sulfate level may trigger comparative dissolution work and, depending on the regulatory pathway, additional bioequivalence risk.

This makes sodium lauryl sulfate a commercially relevant excipient for both generic developers and contract manufacturers. Suppliers with pharmaceutical-grade documentation, reliable regional availability, and change-control discipline have an advantage over low-cost suppliers lacking regulatory support.

What excipient strategy supports JADENU tablet performance?

JADENU’s formulation appears designed around a direct-compression or highly efficient immediate-release manufacturing platform. The combination of microcrystalline cellulose, crospovidone, povidone, surfactant, colloidal silicon dioxide, and magnesium stearate addresses the main manufacturing requirements for a relatively high-dose, poorly soluble drug.

Tablet design

Microcrystalline cellulose provides compactibility without adding excessive tablet weight. Crospovidone supports rapid disintegration through capillary action and swelling-related breakup. Povidone improves cohesion, while colloidal silicon dioxide can improve flow and reduce blend segregation.

Magnesium stearate requires controlled mixing. Over-lubrication can reduce tablet tensile strength and slow wetting or dissolution. This is a known scale-up risk for immediate-release products containing hydrophobic lubricants.

Film coating

The film coat improves swallowability, protects the tablet surface, and permits strength differentiation. Color coding is commercially important because JADENU has multiple strengths and dose adjustments are based on body weight and serum ferritin response.

A generic manufacturer may reproduce the reference coating system or use an alternative colorant and polymer system, provided it meets identity, stability, appearance, dissolution, and regulatory requirements. Coating changes can still create risk if they alter moisture uptake, disintegration, or tablet handling.

What excipients are used in JADENU Sprinkle?

JADENU Sprinkle extends the product platform to patients who cannot reliably swallow tablets. The granule presentation uses an immediate-release excipient approach based on the same broad functional needs: drug wetting, granule integrity, dispersion over soft food, and dose uniformity.[1]

The commercial importance of the granule product is higher in pediatric hematology, sickle-cell disease, thalassemia, and other chronic transfusion populations where long-term adherence is difficult. A successful alternative must address:

• Uniform delivery from the sachet.
• Low dust generation.
• Acceptable taste after sprinkling.
• Compatibility with approved soft foods.
• Stable drug content during storage.
• Consistent administration without chewing or crushing.
• Packaging that protects against moisture.

Taste masking is a potential differentiation area. Deferasirox products can have an unpleasant taste, and excipient choices that improve palatability without delaying release may support pediatric use and adherence.

What patents protect JADENU and when does JADENU lose exclusivity?

JADENU is a small-molecule product, not a biologic. Biosimilar pathways do not apply. Competition proceeds through abbreviated new drug applications, patent certifications, regulatory exclusivity analysis, and product-specific bioequivalence requirements.

The original deferasirox compound and early formulation patent estate provided the main protection for EXJADE and related products. The principal U.S. compound protection expired around 2021, subject to the precise patent term, patent-term adjustment, pediatric exclusivity, and jurisdictional status.[3,4]

The commercial implications are:

Protection category	JADENU relevance
Active-ingredient patents	Largely expired or near expiration in major markets
Original dispersible-tablet patents	Historical protection for EXJADE
Film-coated tablet patents	Potentially relevant to the JADENU dosage form and formulation
Granule or sprinkle patents	Potential protection for administration and product design
Method-of-use patents	May cover iron-overload populations or dosing approaches
Regulatory exclusivity	No longer the main barrier in the mature U.S. market
Trade secrets	Manufacturing process, supplier controls, and analytical methods remain relevant

Patent expiry does not eliminate all entry barriers. Deferasirox has a narrow therapeutic-management context, high dose levels, food-related administration requirements, and dissolution sensitivity. These factors can increase development and post-approval manufacturing risk even after core patent expiry.

What is the Orange Book status of JADENU?

JADENU is listed in the FDA Orange Book as a prescription drug product. The Orange Book identifies approved strengths, dosage forms, therapeutic-equivalence information, and any patents or exclusivity associated with the listed reference product.[3]

Because Orange Book listings can change, the relevant diligence question is not whether JADENU once had listed patents, but whether any unexpired patent remains listed for the exact product and whether a generic applicant has submitted a Paragraph IV certification.

A Paragraph IV challenge asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. For a mature small-molecule product such as deferasirox, Paragraph IV risk is more likely to involve formulation, dosage form, or method-of-use claims than the basic active ingredient.

Which companies are challenging JADENU with generic deferasirox?

Generic competition has developed around deferasirox products in the United States and other markets. Potential competitors include major generic manufacturers and regional suppliers with approved or pending deferasirox tablets, dispersible tablets, or granule products.

The competitive field should be separated into three categories:

1. Generic JADENU-equivalent film-coated tablets.
2. Generic EXJADE-equivalent dispersible tablets.
3. Alternative oral granules or pediatric formulations.

A manufacturer with only a deferasirox active-ingredient supply position may not compete effectively against an integrated developer with finished-dose approval. The key assets are product-specific dissolution data, bioequivalence capability, stable API supply, and regulatory experience with high-dose immediate-release tablets.

Current litigation and Paragraph IV status should be verified through the FDA Orange Book, FDA approval letters, and PACER or court records. Public information does not support treating every generic approval as evidence of a continuing patent dispute.

What commercial opportunities exist in JADENU excipients?

Pharmaceutical-grade excipient supply

The highest-probability opportunity is supplying microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, and coating materials to generic manufacturers. Suppliers can compete through:

• Narrow particle-size specifications.
• Low peroxide and impurity profiles.
• Consistent bulk density.
• Pharmaceutical quality agreements.
• Regional inventory.
• Regulatory documentation.
• Demonstrated compatibility with deferasirox dissolution requirements.

Formulation development services

Contract development organizations can offer generic JADENU development packages covering:

• API particle-size engineering.
• Wetting and dissolution optimization.
• Direct-compression screening.
• Lubrication studies.
• Film-coating development.
• In vitro-in vivo correlation support.
• Comparative dissolution across pH conditions.
• Stability under high-humidity conditions.

Pediatric and adherence products

JADENU Sprinkle creates a differentiated opportunity for sachets, granules, taste-masked products, and patient-friendly packaging. A competing product must preserve immediate release while improving administration acceptability.

Alternative delivery systems

Potential development concepts include orally disintegrating tablets, multiparticulate granules, minitablets, and improved sprinkle systems. These products face regulatory and clinical constraints because changes in dose conversion, food effect, and exposure can make the reference-product relationship difficult to establish.

How strong is the JADENU patent estate?

The estate is weaker against conventional generic entry than it was during the initial EXJADE lifecycle because the fundamental deferasirox compound protection has matured. Remaining strength depends on the scope and enforceability of claims covering:

• Film-coated tablet composition.
• Granule architecture.
• Specific excipient ratios.
• Dissolution profiles.
• Dosing regimens.
• Patient populations.
• Food administration.
• Manufacturing processes.

Formulation patents are strongest when they claim a technically distinctive composition linked to a measurable performance benefit. Claims directed only to routine excipient substitutions may face validity and obviousness challenges. Manufacturing claims can be commercially useful but may be difficult to detect and enforce against a generic producer.

How does JADENU compare with competing iron chelators?

Product	Active ingredient	Administration	Main commercial distinction
JADENU	Deferasirox	Film-coated tablet or granules	Oral convenience and once-daily dosing
EXJADE	Deferasirox	Dispersible tablet	Older presentation with greater preparation burden
Ferriprox	Deferiprone	Tablets or oral solution	Alternative oral chelator with different safety monitoring
Desferal	Deferoxamine	Parenteral infusion	Established efficacy but administration burden

JADENU competes mainly on oral convenience, dosing frequency, and formulation flexibility. Its main commercial risks are generic price erosion, safety-monitoring requirements, and substitution by other oral chelators.

What generic launch scenarios exist for JADENU?

The most likely launch scenario is price competition in standard film-coated tablets after patent and regulatory barriers have cleared. A second scenario involves differentiated generic granules or sprinkle products targeting pediatric and swallowing-impaired patients.

Launch scenario	Probability profile	Commercial effect
Multiple tablet generics	High in mature markets	Rapid price erosion and share loss
Limited generic entry	Moderate if development or supply is difficult	Slower erosion and stronger contract opportunities
Granule-focused competition	Moderate	Preserves niche pricing in pediatric use
New branded reformulation	Lower	Requires clear adherence or tolerability benefit
Biosimilar competition	Not applicable	Deferasirox is a small molecule

What manufacturing and geographic barriers affect JADENU competition?

The active ingredient and finished product require robust control of dissolution, content uniformity, moisture, and dose strength. Regional opportunities differ:

• United States: ANDA competition, Orange Book review, and high sensitivity to generic pricing.
• European Union: national or centralized regulatory pathways, with Exjade and deferasirox products depending on market.
• Emerging markets: demand for lower-cost oral chelation, but greater variation in tender pricing, local registration, and supply-chain requirements.
• Pediatric markets: higher value for sachets, granules, taste masking, and caregiver-friendly packaging.

Manufacturers with reliable deferasirox API access and validated dissolution methods can support both regulated and emerging-market launches. Excipient suppliers with multi-region regulatory files can reduce customer switching costs.

What is the revenue exposure from JADENU generic competition?

JADENU revenue is exposed to standard small-molecule erosion once approved tablet and granule substitutes reach the market. Exposure is greatest in high-volume adult tablet strengths. Granules may retain a smaller but more defensible niche because pediatric administration and taste acceptability create additional product-development requirements.

For Novartis, the commercial defense is more likely to depend on portfolio management, supply reliability, label differentiation, and market-specific pricing than on broad remaining compound exclusivity. For suppliers and generic developers, the opportunity is greatest where excipient quality and formulation execution reduce approval and scale-up risk.

Key Takeaways

• JADENU is a deferasirox film-coated tablet; JADENU Sprinkle is the granule extension.
• Its core excipient strategy combines microcrystalline cellulose, crospovidone, povidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• Sodium lauryl sulfate and crospovidone are important to wetting, disintegration, and dissolution performance.
• The product’s main commercial advantage over EXJADE is administration convenience.
• Deferasirox is a small molecule, so biosimilar risk does not apply.
• Compound-level protection has largely matured, shifting competition toward formulation, manufacturing, and product-specific regulatory barriers.
• The strongest opportunities are generic film-coated tablets, sprinkle granules, excipient supply, taste masking, and formulation-development services.
• Orange Book and court records remain the controlling sources for current patent listings and Paragraph IV litigation.

FAQs

Can sodium lauryl sulfate be replaced in a generic JADENU formulation?

Yes, but replacement may affect wetting, dissolution, bioequivalence, and gastrointestinal tolerability. A substitute surfactant or surfactant-free formulation would require comparative development and regulatory justification.

Is JADENU a biologic requiring biosimilar approval?

No. JADENU contains deferasirox, a chemically synthesized small molecule. Generic competition uses small-molecule abbreviated regulatory pathways rather than biosimilar pathways.

What is the best excipient opportunity in JADENU development?

Pharmaceutical-grade sodium lauryl sulfate, crospovidone, microcrystalline cellulose, and coating systems offer the clearest supply opportunities because they directly affect dissolution, tablet robustness, and manufacturing reproducibility.

Can JADENU granules be marketed as an interchangeable substitute for JADENU tablets?

Not automatically. Granules and tablets are different dosage forms with potentially different administration conditions, exposure, labeling, and bioequivalence requirements. Interchangeability depends on the applicable regulatory approval.

Does JADENU still have meaningful patent protection after deferasirox compound expiry?

Potentially, but remaining protection would depend on unexpired formulation, dosage-form, method-of-use, or manufacturing claims. The basic active-ingredient patent is no longer the primary commercial barrier in mature markets.

References

1. U.S. Food and Drug Administration. (2024). JADENU (deferasirox) tablets and granules: Prescribing information.
2. National Library of Medicine. (2024). JADENU- deferasirox tablet, film coated; JADENU Sprinkle- deferasirox granule. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2015). FDA approves new formulation of Exjade for chronic iron overload.
5. Novartis AG. (2015). Jadenu product and regulatory information.